Details of the Drug Reposition

General Information of This Drug (ID: DMFQEA6)

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Non-small-cell lung cancer	DIS5Y6R9	2C25.Y	Approved	[1]
Melanoma	DIS1RRCY	2C30	Approved	[2]
------------------------------------------------------------------------------------

5 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Esophageal cancer	DISGB2VN	2B70	Phase 3	[3]
Colorectal cancer	DISNH7P9	2B91.Z	Phase 3	[3]
Hepatocellular carcinoma	DIS0J828	2C12.02	Phase 3	[3]
Breast cancer	DIS7DPX1	2C60-2C65	Phase 3	[3]
Renal cell carcinoma	DISQZ2X8	2C90	Phase 3	[3]
------------------------------------------------------------------------------------

3 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 2	[3]
Ovarian cancer	DISZJHAP	2C73	Phase 2	[3]
Prostate cancer	DISF190Y	2C82.0	Phase 2	[3]
------------------------------------------------------------------------------------

1 Application submitted Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Primary mediastinal B-cell lymphoma	DIS7PRLV	2A81	Application submitted	[3]
------------------------------------------------------------------------------------

References

1	Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023 Apr 10;41(11):1992-1998.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)